Answers are grounded in this paper and cite their sources.
Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation. In approximately 50% of patients, mutations have been described in the genes encoding the complement regulators factor H, MCP, and factor I or the activator factor B. We report here mutations in the central component of the complement cascade, C3, in association with aHUS. We describe 9 novel C3 mutations in 14 aHUS patients with a persistently low serum C3 level. We have demonstrated that 5 of these mutations are gain-of-function and 2 are inactivating. This establishes C3 as a susceptibility factor for aHUS.
No takes yet. Share an insight, caveat, or question.
Frémeaux‐Bacchi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: